Financial updates
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2024.
- Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth
- Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023
- RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023
- Joenja® revenue increased by 147% to US$45.0 million in the first full year post-launch and fourth quarter revenue increased by 66% to US$13.1 million, compared to the fourth quarter 2023
- Fourth quarter operating profit increased to US$6.7 million from US$1.1 million in the fourth quarter 2023
- Generated operating profit and positive net cash flows from operations for the second quarter in a row
- Two ongoing Phase II clinical trials of leniolisib for additional primary immunodeficiencies (PIDs) with immune dysregulation, including common variable immunodeficiency (CVID)
- Completed the acquisition of Abliva AB, adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, in line with our vision to become a leading global rare disease company
- Fabrice Chouraqui appointed as Chief Executive Officer and Executive Director at EGM held on March 4, 2025
- 2025 total revenue guidance of US$315 million – US$335 million
- Pharming to host a conference call today at 13:30 CET (8:30 am EDT) (view live webcast)